Moderate To Severe Thyroid Eye Disease clinical trials

Explore recruiting moderate to severe thyroid eye disease clinical trials.

Recruiting moderate to severe thyroid eye disease studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Moderate To Severe Thyroid Eye Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase III, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants with Moderate-to-Severe Thyroid Eye Disease

Germany, Italy, Austria, Hungary, Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

Interventional, open-label, single-group, long-term follow-up trial of Lu AG22515 in patients with moderate-to-severe Thyroid Eye Disease

Poland, Bulgaria, Germany, Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Multicenter, Extension Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Two Doses of Linsitinib in Subjects with Active, Moderate to Severe Thyroid Eye Disease (TED)

Spain, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase III, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants with Moderate-to-Severe Thyroid Eye Disease

Spain, France, Portugal, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects with Active, Moderate to Severe Thyroid Eye Disease (TED)

Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Moderate To Severe Thyroid Eye Disease trials by city

Moderate To Severe Thyroid Eye Disease in Toronto Moderate To Severe Thyroid Eye Disease in Vancouver Moderate To Severe Thyroid Eye Disease in Montreal Moderate To Severe Thyroid Eye Disease in Calgary Moderate To Severe Thyroid Eye Disease in Edmonton Moderate To Severe Thyroid Eye Disease in Ottawa Moderate To Severe Thyroid Eye Disease in Winnipeg Moderate To Severe Thyroid Eye Disease in Quebec City Moderate To Severe Thyroid Eye Disease in Hamilton Moderate To Severe Thyroid Eye Disease in Kitchener Moderate To Severe Thyroid Eye Disease in London Moderate To Severe Thyroid Eye Disease in Halifax Moderate To Severe Thyroid Eye Disease in New York Moderate To Severe Thyroid Eye Disease in Los Angeles Moderate To Severe Thyroid Eye Disease in Chicago Moderate To Severe Thyroid Eye Disease in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease